-45%

est. 2Y upside i

HealthcareSeries C

Candid Health is building a modern medical payments platform that enables healthcare providers to focus on delivering high-quality, affordable and accessible care, rather than spending half their time figuring out how to get paid by insurance.

Rank

#1541

Sector

Healthtech

Est. Liquidity

~3Y

Data Quality

Data: Medium

Candid Health presents a moderate upside opportunity for a job seeker, driven by its strong competitive moat and impressive recent growth, including 'tripled claims volume' and '240% YoY Growth' in 2025.

Last updated: March 10, 2026

Bull (40%)+175%

Candid Health continues its rapid expansion, leveraging its AI-driven platform to capture significant market share from legacy RCM solutions. With 'tripled claims volume' and '240% YoY Growth' in 2025, the company achieves $150M+ ARR by 2027, leading to an acquisition or IPO at a $687.5M valuation (2.75x current), providing substantial returns for common shareholders after accounting for liquidation preferences.

Base (30%)+30%

Candid Health maintains solid growth, expanding its customer base and platform capabilities. It successfully navigates competitive pressures, reaching $75M ARR by 2027. An exit at a $325M valuation (1.3x current) allows for a moderate return for common shareholders after the $100M liquidation preference.

Bear (30%)-50%

Increased competition from incumbents or slower-than-expected adoption in the highly regulated healthcare market leads to decelerated growth. The company struggles to justify its current valuation, resulting in a down round or exit at $125M (0.5x current), which, after the $100M liquidation preference, severely diminishes or wipes out common stock value.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

40%

Investors hold $100M in liquidation preferences, meaning common shareholders would only see returns if the company exits above $100M.

Dilution Risk

moderate

As a Series C company, further funding rounds are likely, which could lead to additional dilution for existing equity holders.

Secondary Liquidity

moderate

Accredited investors can buy pre-IPO stock in Candid Health through platforms like EquityZen, indicating some secondary market activity.

Engineering — 16 roles

People — 4 roles

Sales — 4 roles

Billing Team — 3 roles

Delivery / Customer Operations — 2 roles

Finance — 2 roles

Marketing — 2 roles

Design — 1 role

Facilities — 1 role

Leadership Overhead — 1 role

Legal — 1 role

Product — 1 role

View all 38 open roles at Candid Health →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Candid Health's data — designed to show you've done your homework.

  • 1

    “Given the strong growth in claims volume and charges, how is Candid Health planning to scale its operations and customer support while maintaining its 'over 95% touchless claim rates' and 'payer net collection rates exceeding 97%'?”

  • 2

    “With dominant incumbents like Waystar and R1 RCM in the RCM space, what specific strategies is Candid Health employing to continue differentiating its AI-driven, preventative approach and convert larger enterprise clients?”

  • 3

    “Considering the Series C funding and the current $250M valuation, what is the anticipated timeline and strategy for a liquidity event (e.g., IPO or acquisition), and how does the company plan to manage the existing liquidation preferences for future employee equity value?”

Community

Valuation Sentiment

Our model estimates -45% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.